BLVRB / biliverdin reductase B Protein (His Tag)

Biliverdin reductase B (flavin reductase (NADPH)) Protein Datasheet

BLVRB / biliverdin reductase B Protein Product Information

• Synonym: BVRB, FLR, MGC117413, SDR43U1
• Protein Construction: A DNA sequence encoding the human BLVRB (P30043) (Ala 2-Gln 206) was expressed, with a polyhistide tag at the N-terminus.
• Source: Human
• Expression Host: E. Coli

BLVRB / biliverdin reductase B Protein QC Testing

• Purity: > 97 % as determined by SDS-PAGE.
• Endotoxin: Please contact us for more information.
• Stability: Samples are stable for up to twelve months from date of receipt at -70℃
• Predicted N terminal: Met
• Molecular Mass: The recombinant human BLVRB consisting of 216 amino acids and has a calculated molecular mass of 23.5 KDa. It migrates as a kDa band in SDS-PAGE under reducing conditions as predicted.
• Formulation: Lyophilized from 0.2μm filtered solution of PBS.0.02%Brij35, 10%glycerol, pH 7.5
  1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
  2. Please contact us for any concerns or special requirements.
• SDS-PAGE: BLVRB / biliverdin reductase B protein

BLVRB / biliverdin reductase B Protein Usage Guide

• Storage: Store it under sterile conditions at -70℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: A hardcopy of COA with reconstitution instruction is sent along with the products. Please refer to it for detailed information.

BLVRB / biliverdin reductase B Protein Description

Biliverdin reductase (hBVR) is a serine/threonine kinase that catalyzes reduction of the heme oxygenase (HO) activity product, biliverdin, to bilirubin. BVR consists of an N-terminal dinucleotide-binding domain (Rossmann-fold) and a C-terminal domain that contains a six-stranded β-sheet that is flanked on one face by several α-helices. The C-terminal and N-terminal domains interact extensively, forming the active site cleft at their interface. Biliverdin reductase (BVR) catalyzes the last step in heme degradation by reducing the γ-methene bridge of the open tetrapyrrole, biliverdin IXα, to bilirubin with the concomitant oxidation of a β-nicotinamide adenine dinucleotide (NADH) or β-nicotinamide adenine dinucleotide phosphate (NADPH) cofactor. It is now recognized that human BVR (hBVR) is a dual-specificity kinase (Ser/Thr and Tyr) upstream activator of the insulin/insulin growth factor-1 (IGF-1) and mitogen-activated protein kinase (MAPK) signaling pathways. Human BVR (hBVR) is essential for MAPK–extracellular signal-regulated kinase (ERK)1/2 (MEK)–eukaryotic-like protein kinase (Elk) signaling and has been identified as the cytoplasm-nuclear heme transporter of ERK1/2 and hematin, the key components of stress-responsive gene expression.

References

1. Kapitulnik J. et al., 2009, Trends in Pharmacological Sciences. 30 (3): 129-37.
2. Ahmad Z. et al., 2002, Journal of Biological Chemistry. 277: 9226-32.
3. Whitby FG. et al., 2002, Journal of Molecular Biology. 319 (5) 1199-210.